ReviewAnnals of surgical oncology2025
ASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk.
Review in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Surgical Approach on Survival and Recurrence in Borderline and Malignant Phyllodes Tumours: A Systematic Review and Meta-Analysis.ANZ journal of surgery · 2026Pooled it
- Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach.Current treatment options in oncology · 2026Review
- Article
- Review
- Colossal well-differentiated liposarcoma of the small bowel mesentery: A case report.World journal of gastrointestinal oncology · 2026Article
- Development and temporal validation of a machine learning-based model to predict postoperative recurrence and guide adjuvant radiotherapy in patients with soft tissue sarcoma: a retrospective cohort study.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies. While surgery remains the mainstay of treatment, with the goal of achieving negative margins and preserving limb function, radiotherapy is frequently employed to reduce the risk of local recurrence. Systemic therapies, including chemotherapy and immunotherapy, are increasingly being explored in both the neoadjuvant and adjuvant settings. Recent evidence suggests that chemotherapy may provide a survival benefit in selected high-risk patients. Additionally, emerging data on immune checkpoint inhibitors indicate potential efficacy in specific histologic types and in combination with radiotherapy. Given the complexity of diagnosis and treatment, centralization of care in specialized sarcoma centers is critical to ensure optimal patient outcomes.
Indexed as
Identifiers
40931305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.